Hypolipidemic Formula Stability via pH Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing pharmaceutical compositions of hypolipidemic compounds of formula (I) are prone to oxidation, alkaline, and acid hydrolysis, leading to stability issues during synthesis, purification, and storage, requiring costly and difficult-to-manage packaging conditions, and result in increased impurity levels over time.
Innovation Solution
The formulation maintains a microenvironmental pH above 7 using suitable alkalinizers, combined with antioxidants and chelating agents, to stabilize the compounds and restrict impurity growth, thereby overcoming stability challenges and packaging requirements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If the compound of formula (I) is stored in bulk form without special packaging, then storage and handling become easier, but the compound is prone to oxidation and degradation
Solution Approach 1:
The patent introduces an intermediary substance (antioxidant or pH-modifying agent) that mediates between the compound and the degrading environment. This intermediary protects the compound from oxidation and hydrolysis without requiring special packaging conditions, thus resolving the contradiction between ease of storage and stability.
Solution Approach 2:
The patent changes the chemical parameter (pH) of the formulation environment to above 7 by adding alkaline substances. This parameter change prevents acid-catalyzed hydrolysis and reduces oxidation susceptibility, allowing the compound to be stored under normal conditions without special packaging while maintaining stability.
2Reliability
If protective gas packaging is used to prevent oxidation, then compound stability is improved, but packaging cost and complexity increase
Solution Approach 1:
The patent converts the harmful effect of atmospheric oxygen into a beneficial situation by adding antioxidants that actively scavenge oxygen and free radicals. This transforms the oxidizing environment into a protective one, eliminating the need for protective gas packaging while maintaining stability.
Solution Approach 2:
By changing the chemical environment through pH modification and antioxidant addition, the patent makes the compound stable in normal atmospheric conditions, thereby eliminating the need for complex protective gas packaging systems.
3Reliability
If substantial amounts of stabilizers are added to prevent oxidation, then compound stability is improved, but formulation complexity and cost increase
Solution Approach 1:
The patent applies local quality by creating a specific microenvironment (pH > 7) around the compound through pH-modifying agents. This localized chemical environment provides protection without requiring substantial amounts of stabilizers throughout the entire formulation, reducing formulation complexity.
4Object-affected harmful factors
If the compound is stored under airtight conditions with protective gas, then oxidation is prevented, but handling and industrial scale production become difficult
Solution Approach 1:
The patent makes the compound self-protecting by incorporating antioxidants and pH-modifying agents that provide inherent stability. The formulation protects itself from oxidation and hydrolysis without requiring external protective measures like airtight packaging with protective gas, enabling easy handling and industrial-scale production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stabilization of the pharmaceutical composition using alkalinizers, antioxidants, and chelating agents effectively restricts impurity growth, ensuring long-term stability and meeting regulatory requirements, making the compound suitable for clinical trials and commercial use.
Implementation Method 1
when suitable alkalinizer(s) are added which maintains the pH of the formulation above 7, the increase in the level of said impurity is restricted
Implementation Method 2
The compounds of formula (I) are susceptible to oxidation, alkaline & acid hydrolysis and stress degradation during synthesis, purification and storage of the drug substance
Implementation Method 3
The compounds of formula (I) are susceptible to oxidation, alkaline & acid hydrolysis and stress degradation
Implementation Method 4
Use of a suitable antioxidant(s) and chelating agent(s) further stabilizes the formulation
Data Source
AI summary
The present invention relates to the stable pharmaceutical composition of a suitable hypolipidemic agent. Preferably, the present invention discloses novel formulations of the compound of formula (I), or pharmaceutically acceptable salts of compounds of formula (I). More particularly the present invention relates to the stable pharmaceutical composition of compounds of formula (I) comprising compounds of formula (I) or its pharmaceutically acceptable salts, wherein the pH of the formulation is maintained above 7. formula (I).